Literature DB >> 1100302

Bioavailability of dexamethasone. II. Dexamethasone phosphate.

L E Hare, K C Yeh, C A Ditzler, F G McMahon, D E Duggan.   

Abstract

Plasma levels of dexamethasone phosphate (DP) and dexamethasone free alcohol (DA) were determined by a modification of existing radioimmunoassay methodology following intravenous administration of DP in man. Areas under DA plasma profiles were a linear function of DP dosage over the 40-fold range 0.05 to 2.0 mg/kg, and, by comparison with values obtained after DA was intravenously administered, indicated an overall conversion of DP to DA of 90%. The first-order rate constant for the conversion, 4.03 hr-1, was approximately 25 times that for hydrolysis in whole blood incubated in vitro. This relationship as well as disposition kinetics suggested that the major component of DP hydrolysis occurs within highly perfused organ(s) comprising the central kinetic compartment. Eighteen subjects were studied in a crossover experiment, and no significant differences were observed in best-fit parameters for the 4 mg/ml parenteral solution of DP in current use and an experimental high potency preparation of 24 mg/ml.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1100302     DOI: 10.1002/cpt1975183330

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  Stability of dexamethasone sodium phosphate in rat plasma.

Authors:  Mahesh N Samtani; William J Jusko
Journal:  Int J Pharm       Date:  2005-09-14       Impact factor: 5.875

2.  The pharmacokinetics of low-dose dexamethasone in congenital adrenal hyperplasia.

Authors:  M C Young; N Cook; G F Read; I A Hughes
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose.

Authors:  N A Al Katheeri; I A Wasfi; M Lambert; A Saeed
Journal:  Vet Res Commun       Date:  2004-08       Impact factor: 2.459

Review 4.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Disposition of synethetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults.

Authors:  S E Tsuei; R G Moore; J J Ashley; W G McBride
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

Review 6.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

7.  The pharmacokinetics of single high doses of dexamethasone in cancer patients.

Authors:  M E Brady; G P Sartiano; S L Rosenblum; N E Zaglama; C T Bauguess
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Phosphoryloxymethyl carbamates and carbonates--novel water-soluble prodrugs for amines and hindered alcohols.

Authors:  M Safadi; R Oliyai; V J Stella
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

9.  Pharmacokinetics of betamethasone in healthy adults after intravenous administration.

Authors:  M C Petersen; R L Nation; W G McBride; J J Ashley; R G Moore
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man.

Authors:  S Miyabo; T Nakamura; S Kuwazima; S Kishida
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.